The market for neurological biomarkers is anticipated to grow in the coming years. The driving factors that are responsible for the growth of the market are rise in the geriatric population, growing genetic disorders, rising advancement in the field of biotechnology and others. The genome editing technologies are likely to create growth opportunities for the growth of the market during the forecast period.
Biomarkers are the molecules that indicates about the presence of a disease. The biomarkers of the neurological diseases were not that accessible in earlier days, however the advancements in the technology has enabled to track the health condition of the brain by measuring the biomarkers. This helps in the earlier detection of a disease, less invasive diagnostics and enables faster drug development and is expected to be the effective treatment.
The report analyzes factors affecting neurological biomarker market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the neurological biomarker market in these regions.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global neurological biomarker market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The neurological biomarker market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The reports cover key developments in the neurological biomarker market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market payers from Neurological Biomarker market are anticipated to lucrative growth opportunities in the future with the rising demand for neurological biomarker market in the global market. Below mentioned is the list of few companies engaged in the neurological biomarker market.
1. Thermo Fisher Scientific Inc
3. Banyan Biomarkers, Inc
5. Myriad RBM
6. Bio-Rad Laboratories, Inc
8. Athena Diagnostics
9. Immunarray pvt. Ltd
10. Diagenic Asa
The global neurological biomarker market segment is segmented on the basis of product, application and end user. Based on product the market is classified as proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker and others. Based on the application the market is divided into alzheimer's disease, parkinson's disease, schizophrenia, huntington's disease, spinal muscular atrophy and others. The market on the basis of end user is classified as pharmaceutical and biotechnology companies, clinical diagnostics and research organizations.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Media, Healthcare and Telecommunication industries.